Skip to content
2000
image of Methyl (Z)-2-(Isothioureidomethyl)-2-pentenoate Hydrobromide Induces Cell Cycle Arrest and Disrupts Mitosis in a Melanoma Cell Line

Abstract

Introduction/Objective

Cancer is a global health burden. Despite advances in early detection and therapeutics, cancer prevalence continues to increase, underscoring the need for innovative therapeutic strategies. Dysregulation of cell death mechanisms is a hallmark of cancer that can lead to apoptosis evasion, which strongly contributes to tumor progression and therapy resistance. Isothiouronium salts have attracted attention as promising antitumor agents. This study aimed to evaluate the antitumor effect of an isothiouronium salt (IS-MF08) on the B16F10 melanoma cell line.

Methods

The antitumor properties of IS-MF08 were investigated by incubating B16F10 cells with the compound at different concentrations. Cytotoxicity was determined by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay, cell cycle arrest and cell death mechanisms by flow cytometry, and morphological alterations by transmission electron microscopy. Physicochemical parameters related to drug-likeness were predicted using the SwissADME tool.

Results

IS-MF08 was cytotoxic to melanoma cells, triggering cell cycle arrest and disrupting mitosis. The mechanism of cell death was compatible with apoptosis, as indicated by annexin V-FITC experiments and the relevant morphological changes in cell structure observed by transmission electron microscopy. SwissADME predicted that IS-MF08 has good physicochemical properties related to absorption and permeation.

Conclusion

The numerous mechanisms of cell death triggered by IS-MF08 and its drug-likeness make it an interesting molecule in the search for new antitumor compounds, contributing to therapies targeting the dysregulation of cellular mechanisms such as apoptosis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206358941250413154017
2025-04-24
2025-09-27

  • From This Site

    /content/journals/acamc/10.2174/0118715206358941250413154017
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Kocarnik J.M. Compton K. Dean F.E. Fu W. Gaw B.L. Harvey J.D. Henrikson H.J. Lu D. Pennini A. Xu R. Ababneh E. Abbasi-Kangevari M. Abbastabar H. Abd-Elsalam S.M. Abdoli A. Abedi A. Abidi H. Abolhassani H. Adedeji I.A. Adnani Q.E.S. Advani S.M. Afzal M.S. Aghaali M. Ahinkorah B.O. Ahmad S. Ahmad T. Ahmadi A. Ahmadi S. Ahmed Rashid T. Ahmed Salih Y. Akalu G.T. Aklilu A. Akram T. Akunna C.J. Al Hamad H. Alahdab F. Al-Aly Z. Ali S. Alimohamadi Y. Alipour V. Aljunid S.M. Alkhayyat M. Almasi-Hashiani A. Almasri N.A. Al-Maweri S.A.A. Almustanyir S. Alonso N. Alvis-Guzman N. Amu H. Anbesu E.W. Ancuceanu R. Ansari F. Ansari-Moghaddam A. Antwi M.H. Anvari D. Anyasodor A.E. Aqeel M. Arabloo J. Arab-Zozani M. Aremu O. Ariffin H. Aripov T. Arshad M. Artaman A. Arulappan J. Asemi Z. Asghari Jafarabadi M. Ashraf T. Atorkey P. Aujayeb A. Ausloos M. Awedew A.F. Ayala Quintanilla B.P. Ayenew T. Azab M.A. Azadnajafabad S. Azari Jafari A. Azarian G. Azzam A.Y. Badiye A.D. Bahadory S. Baig A.A. Baker J.L. Balakrishnan S. Banach M. Bärnighausen T.W. Barone-Adesi F. Barra F. Barrow A. Behzadifar M. Belgaumi U.I. Bezabhe W.M.M. Bezabih Y.M. Bhagat D.S. Bhagavathula A.S. Bhardwaj N. Bhardwaj P. Bhaskar S. Bhattacharyya K. Bhojaraja V.S. Bibi S. Bijani A. Biondi A. Bisignano C. Bjørge T. Bleyer A. Blyuss O. Bolarinwa O.A. Bolla S.R. Braithwaite D. Brar A. Brenner H. Bustamante-Teixeira M.T. Butt N.S. Butt Z.A. Caetano dos Santos F.L. Cao Y. Carreras G. Catalá-López F. Cembranel F. Cerin E. Cernigliaro A. Chakinala R.C. Chattu S.K. Chattu V.K. Chaturvedi P. Chimed-Ochir O. Cho D.Y. Christopher D.J. Chu D.T. Chung M.T. Conde J. Cortés S. Cortesi P.A. Costa V.M. Cunha A.R. Dadras O. Dagnew A.B. Dahlawi S.M.A. Dai X. Dandona L. Dandona R. Darwesh A.M. das Neves J. De la Hoz F.P. Demis A.B. Denova-Gutiérrez E. Dhamnetiya D. Dhimal M.L. Dhimal M. Dianatinasab M. Diaz D. Djalalinia S. Do H.P. Doaei S. Dorostkar F. dos Santos Figueiredo F.W. Driscoll T.R. Ebrahimi H. Eftekharzadeh S. El Tantawi M. El-Abid H. Elbarazi I. Elhabashy H.R. Elhadi M. El-Jaafary S.I. Eshrati B. Eskandarieh S. Esmaeilzadeh F. Etemadi A. Ezzikouri S. Faisaluddin M. Faraon E.J.A. Fares J. Farzadfar F. Feroze A.H. Ferrero S. Ferro Desideri L. Filip I. Fischer F. Fisher J.L. Foroutan M. Fukumoto T. Gaal P.A. Gad M.M. Gadanya M.A. Gallus S. Gaspar Fonseca M. Getachew Obsa A. Ghafourifard M. Ghashghaee A. Ghith N. Gholamalizadeh M. Gilani S.A. Ginindza T.G. Gizaw A.T.T. Glasbey J.C. Golechha M. Goleij P. Gomez R.S. Gopalani S.V. Gorini G. Goudarzi H. Grosso G. Gubari M.I.M. Guerra M.R. Guha A. Gunasekera D.S. Gupta B. Gupta V.B. Gupta V.K. Gutiérrez R.A. Hafezi-Nejad N. Haider M.R. Haj-Mirzaian A. Halwani R. Hamadeh R.R. Hameed S. Hamidi S. Hanif A. Haque S. Harlianto N.I. Haro J.M. Hasaballah A.I. Hassanipour S. Hay R.J. Hay S.I. Hayat K. Heidari G. Heidari M. Herrera-Serna B.Y. Herteliu C. Hezam K. Holla R. Hossain M.M. Hossain M.B.H. Hosseini M.S. Hosseini M. Hosseinzadeh M. Hostiuc M. Hostiuc S. Househ M. Hsairi M. Huang J. Hugo F.N. Hussain R. Hussein N.R. Hwang B.F. Iavicoli I. Ibitoye S.E. Ida F. Ikuta K.S. Ilesanmi O.S. Ilic I.M. Ilic M.D. Irham L.M. Islam J.Y. Islam R.M. Islam S.M.S. Ismail N.E. Isola G. Iwagami M. Jacob L. Jain V. Jakovljevic M.B. Javaheri T. Jayaram S. Jazayeri S.B. Jha R.P. Jonas J.B. Joo T. Joseph N. Joukar F. Jürisson M. Kabir A. Kahrizi D. Kalankesh L.R. Kalhor R. Kaliyadan F. Kalkonde Y. Kamath A. Kameran Al-Salihi N. Kandel H. Kapoor N. Karch A. Kasa A.S. Katikireddi S.V. Kauppila J.H. Kavetskyy T. Kebede S.A. Keshavarz P. Keykhaei M. Khader Y.S. Khalilov R. Khan G. Khan M. Khan M.N. Khan M.A.B. Khang Y.H. Khater A.M. Khayamzadeh M. Kim G.R. Kim Y.J. Kisa A. Kisa S. Kissimova-Skarbek K. Kopec J.A. Koteeswaran R. Koul P.A. Koulmane Laxminarayana S.L. Koyanagi A. Kucuk Bicer B. Kugbey N. Kumar G.A. Kumar N. Kumar N. Kurmi O.P. Kutluk T. La Vecchia C. Lami F.H. Landires I. Lauriola P. Lee S. Lee S.W.H. Lee W.C. Lee Y.H. Leigh J. Leong E. Li J. Li M.C. Liu X. Loureiro J.A. Lunevicius R. Magdy Abd El Razek M. Majeed A. Makki A. Male S. Malik A.A. Mansournia M.A. Martini S. Masoumi S.Z. Mathur P. McKee M. Mehrotra R. Mendoza W. Menezes R.G. Mengesha E.W. Mesregah M.K. Mestrovic T. Miao Jonasson J. Miazgowski B. Miazgowski T. Michalek I.M. Miller T.R. Mirzaei H. Mirzaei H.R. Misra S. Mithra P. Moghadaszadeh M. Mohammad K.A. Mohammad Y. Mohammadi M. Mohammadi S.M. Mohammadian-Hafshejani A. Mohammed S. Moka N. Mokdad A.H. Molokhia M. Monasta L. Moni M.A. Moosavi M.A. Moradi Y. Moraga P. Morgado-da-Costa J. Morrison S.D. Mosapour A. Mubarik S. Mwanri L. Nagarajan A.J. Nagaraju S.P. Nagata C. Naimzada M.D. Nangia V. Naqvi A.A. Narasimha Swamy S. Ndejjo R. Nduaguba S.O. Negoi I. Negru S.M. Neupane Kandel S. Nguyen C.T. Nguyen H.L.T. Niazi R.K. Nnaji C.A. Noor N.M. Nuñez-Samudio V. Nzoputam C.I. Oancea B. Ochir C. Odukoya O.O. Ogbo F.A. Olagunju A.T. Olakunde B.O. Omar E. Omar Bali A. Omonisi A.E.E. Ong S. Onwujekwe O.E. Orru H. Ortega-Altamirano D.V. Otstavnov N. Otstavnov S.S. Owolabi M.O. P A M. Padubidri J.R. Pakshir K. Pana A. Panagiotakos D. Panda-Jonas S. Pardhan S. Park E.C. Park E.K. Pashazadeh Kan F. Patel H.K. Patel J.R. Pati S. Pattanshetty S.M. Paudel U. Pereira D.M. Pereira R.B. Perianayagam A. Pillay J.D. Pirouzpanah S. Pishgar F. Podder I. Postma M.J. Pourjafar H. Prashant A. Preotescu L. Rabiee M. Rabiee N. Radfar A. Radhakrishnan R.A. Radhakrishnan V. Rafiee A. Rahim F. Rahimzadeh S. Rahman M. Rahman M.A. Rahmani A.M. Rajai N. Rajesh A. Rakovac I. Ram P. Ramezanzadeh K. Ranabhat K. Ranasinghe P. Rao C.R. Rao S.J. Rawassizadeh R. Razeghinia M.S. Renzaho A.M.N. Rezaei N. Rezaei N. Rezapour A. Roberts T.J. Rodriguez J.A.B. Rohloff P. Romoli M. Ronfani L. Roshandel G. Rwegerera G.M. S M. Sabour S. Saddik B. Saeed U. Sahebkar A. Sahoo H. Salehi S. Salem M.R. Salimzadeh H. Samaei M. Samy A.M. Sanabria J. Sankararaman S. Santric-Milicevic M.M. Sardiwalla Y. Sarveazad A. Sathian B. Sawhney M. Saylan M. Schneider I.J.C. Sekerija M. Seylani A. Shafaat O. Shaghaghi Z. Shaikh M.A. Shamsoddin E. Shannawaz M. Sharma R. Sheikh A. Sheikhbahaei S. Shetty A. Shetty J.K. Shetty P.H. Shibuya K. Shirkoohi R. Shivakumar K.M. Shivarov V. Siabani S. Siddappa Malleshappa S.K. Silva D.A.S. Singh J.A. Sintayehu Y. Skryabin V.Y. Skryabina A.A. Soeberg M.J. Sofi-Mahmudi A. Sotoudeh H. Steiropoulos P. Straif K. Subedi R. Sufiyan M.B. Sultan I. Sultana S. Sur D. Szerencsés V. Szócska M. Tabarés-Seisdedos R. Tabuchi T. Tadbiri H. Taherkhani A. Takahashi K. Talaat I.M. Tan K.K. Tat V.Y. Tedla B.A.A. Tefera Y.G. Tehrani-Banihashemi A. Temsah M.H. Tesfay F.H. Tessema G.A. Thapar R. Thavamani A. Thoguluva Chandrasekar V. Thomas N. Tohidinik H.R. Touvier M. Tovani-Palone M.R. Traini E. Tran B.X. Tran K.B. Tran M.T.N. Tripathy J.P. Tusa B.S. Ullah I. Ullah S. Umapathi K.K. Unnikrishnan B. Upadhyay E. Vacante M. Vaezi M. Valadan Tahbaz S. Velazquez D.Z. Veroux M. Violante F.S. Vlassov V. Vo B. Volovici V. Vu G.T. Waheed Y. Wamai R.G. Ward P. Wen Y.F. Westerman R. Winkler A.S. Yadav L. Yahyazadeh Jabbari S.H. Yang L. Yaya S. Yazie T.S.Y. Yeshaw Y. Yonemoto N. Younis M.Z. Yousefi Z. Yu C. Yuce D. Yunusa I. Zadnik V. Zare F. Zastrozhin M.S. Zastrozhina A. Zhang J. Zhong C. Zhou L. Zhu C. Ziapour A. Zimmermann I.R. Fitzmaurice C. Murray C.J.L. Force L.M. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019. JAMA Oncol. 2022 8 3 420 444 10.1001/jamaoncol.2021.6987 34967848
    [Google Scholar]
  3. Bray F. Laversanne M. Sung H. Ferlay J. Siegel R.L. Soerjomataram I. Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 74 3 229 263 10.3322/caac.21834 38572751
    [Google Scholar]
  4. Siegel R.L. Kratzer T.B. Giaquinto A.N. Sung H. Jemal A. Cancer statistics, 2025. CA Cancer J. Clin. 2025 75 1 10 45 10.3322/caac.21871 39817679
    [Google Scholar]
  5. Corn B.W. Feldman D.B. Cancer statistics, 2025: A hinge moment for optimism to morph into hope? CA Cancer J. Clin. 2025 75 1 7 9 10.3322/caac.21877 39817675
    [Google Scholar]
  6. Prkačin I. Mokos M. Ferara N. Šitum M. Melanoma’s new frontier: Exploring the latest advances in blood-based biomarkers for melanoma. Cancers (Basel) 2024 16 24 4219 10.3390/cancers16244219 39766118
    [Google Scholar]
  7. Carr S. Smith C. Wernberg J. Epidemiology and risk factors of melanoma. Surg. Clin. North Am. 2020 100 1 1 12 10.1016/j.suc.2019.09.005 31753105
    [Google Scholar]
  8. Atkins M.B. Curiel-Lewandrowski C. Fisher D.E. Swetter S.M. Tsao H. Aguirre-Ghiso J.A. Soengas M.S. Weeraratna A.T. Flaherty K.T. Herlyn M. Sosman J.A. Tawbi H.A. Pavlick A.C. Cassidy P.B. Chandra S. Chapman P.B. Daud A. Eroglu Z. Ferris L.K. Fox B.A. Gershenwald J.E. Gibney G.T. Grossman D. Hanks B.A. Hanniford D. Hernando E. Jeter J.M. Johnson D.B. Khleif S.N. Kirkwood J.M. Leachman S.A. Mays D. Nelson K.C. Sondak V.K. Sullivan R.J. Merlino G. The State of Melanoma: Emergent challenges and opportunities. Clin. Cancer Res. 2021 27 10 2678 2697 10.1158/1078‑0432.CCR‑20‑4092 33414132
    [Google Scholar]
  9. Long G.V. Swetter S.M. Menzies A.M. Gershenwald J.E. Scolyer R.A. Cutaneous melanoma. Lancet 2023 402 10400 485 502 10.1016/S0140‑6736(23)00821‑8 37499671
    [Google Scholar]
  10. Domingues B. Lopes J. Soares P. Pópulo H. Melanoma treatment in review. ImmunoTargets Ther. 2018 7 35 49 10.2147/ITT.S134842 29922629
    [Google Scholar]
  11. Advancing cancer therapy. Nat. Can. 2021 2 3 245 246 10.1038/s43018‑021‑00192‑x 35121963
    [Google Scholar]
  12. Soengas M.S. Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003 22 20 3138 3151 10.1038/sj.onc.1206454 12789290
    [Google Scholar]
  13. Elmore S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007 35 4 495 516 10.1080/01926230701320337 17562483
    [Google Scholar]
  14. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J. Cell. Mol. Med. 2009 13 7 1221 1227 10.1111/j.1582‑4934.2009.00748.x 19382915
    [Google Scholar]
  15. Chen P. Ji X.Y. Feng J.T. Wang X.Q. Zhang B. The synergistic mechanism of chelidonium majus alkaloids on melanoma treatment via a multi-strategy insight. Molecules 2024 29 22 5412 10.3390/molecules29225412 39598801
    [Google Scholar]
  16. Neophytou C.M. Trougakos I.P. Erin N. Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel) 2021 13 17 4363 10.3390/cancers13174363 34503172
    [Google Scholar]
  17. Hanahan D. Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
    [Google Scholar]
  18. Koolivand Z. Bahreini F. Rayzan E. Rezaei N. Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations. Heliyon 2025 11 1 e41355 10.1016/j.heliyon.2024.e41355 39811307
    [Google Scholar]
  19. Tarhini A.A. Kirkwood J.M. Tawbi H. Gooding W.E. Islam M.F. Agarwala S.S. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 2008 112 5 1131 1138 10.1002/cncr.23284 18286511
    [Google Scholar]
  20. Jan R. Chaudhry G.S. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv. Pharm. Bull. 2019 9 2 205 218 10.15171/apb.2019.024 31380246
    [Google Scholar]
  21. Ashkenazi A. Herbst R.S. To kill a tumor cell: The potential of proapoptotic receptor agonists. J. Clin. Invest. 2008 118 6 1979 1990 10.1172/JCI34359 18523647
    [Google Scholar]
  22. Fulda S. Targeting apoptosis for anticancer therapy. Semin. Cancer Biol. 2015 31 84 88 10.1016/j.semcancer.2014.05.002 24859747
    [Google Scholar]
  23. Yu C.T.R. Liao Y.T.A. Chiang C.Y.N. Chen J.M.M. Pan H.Y.B. Pan C.Y. Jiang W.J. Tsai J.R. Yang T.Y. Teng C.L.J. Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. J. Transl. Med. 2024 22 1 1095 10.1186/s12967‑024‑05920‑2 39623468
    [Google Scholar]
  24. Bella M.D. Tait A. Parenti C. Bondi M. Quaglio G. S-aryl(tetramethyl)isothiouronium salts as possible antimicrobial agents, I. Arch. Pharm. (Weinheim) 1986 319 5 451 456 10.1002/ardp.19863190513 3089193
    [Google Scholar]
  25. Venkatachalam T. Vassilev A. Benyunov A. Grigoriants O. Tibbles H. Uckun F. Stereochemistry as a determinant of the anti-leukemic potency of halopyridyl and thiazolyl thiourea compounds. Lett. Drug Des. Discov. 2007 4 5 318 326 10.2174/157018007780867870
    [Google Scholar]
  26. El-Henawy A. Khowdiary M. Badawi A. Soliman H. In vivo anti-leukemia, quantum chemical calculations and ADMET investigations of some quaternary and isothiouronium surfactants. Pharmaceuticals (Basel) 2013 6 5 634 649 10.3390/ph6050634 24276171
    [Google Scholar]
  27. Ferreira M. Assunção L.S. Filippin-Monteiro F.B. Creczynski-Pasa T.B. Sá M.M. Synthesis of 1,3-thiazine-2,4-diones with potential anticancer activity. Eur. J. Med. Chem. 2013 70 411 418 10.1016/j.ejmech.2013.10.017 24177368
    [Google Scholar]
  28. Cisilotto J. Ferreira M. Filippin-Monteiro F. Bortoluzzi A. Sa M. Creczynski-Pasa T. Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells. Anticancer. Agents Med. Chem. 2015 15 3 353 362 10.2174/1871520614666141130125148 25469513
    [Google Scholar]
  29. Cohen S. Gelber C. Natan M. Banin E. Corem-Salkmon E. Margel S. Synthesis and characterization of crosslinked polyisothiouronium methylstyrene nanoparticles of narrow size distribution for antibacterial and antibiofilm applications. J. Nanobiotechnology 2016 14 1 56 10.1186/s12951‑016‑0208‑7 27388790
    [Google Scholar]
  30. Wang D.P. Wu L.H. Li R. He N. Zhang Q.Y. Zhao C.Y. Jiang T. A novel aldisine derivative exhibits potential antitumor effects by targeting JAK/STAT3 signaling. Mar. Drugs 2023 21 4 218 10.3390/md21040218 37103357
    [Google Scholar]
  31. Ferreira M. Assunção L.S. Silva A.H. Filippin-Monteiro F.B. Creczynski-Pasa T.B. Sá M.M. Allylic isothiouronium salts: The discovery of a novel class of thiourea analogues with antitumor activity. Eur. J. Med. Chem. 2017 129 151 158 10.1016/j.ejmech.2017.02.013 28222315
    [Google Scholar]
  32. Yu H. Adedoyin A. ADME–Tox in drug discovery: Integration of experimental and computational technologies. Drug Discov. Today 2003 8 18 852 861 10.1016/S1359‑6446(03)02828‑9 12963322
    [Google Scholar]
  33. Cheng F. Li W. Liu G. Tang Y. In silico ADMET prediction: Recent advances, current challenges and future trends. Curr. Top. Med. Chem. 2013 13 11 1273 1289 10.2174/15680266113139990033 23675935
    [Google Scholar]
  34. van de Waterbeemd H. Gifford E. ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug Discov. 2003 2 3 192 204 10.1038/nrd1032 12612645
    [Google Scholar]
  35. Zaman H. Saeed A. Ismail H. Rashid M. Unveiling the cyclopropyl appended acyl thiourea derivatives as antimicrobial, α-amylase and proteinase K inhibitors: Design, synthesis, biological evaluation, molecular docking, DFT and ADMET studies. Arch. Biochem. Biophys. 2025 765 110304 10.1016/j.abb.2025.110304 39814157
    [Google Scholar]
  36. Ekins S. Lane T.R. Urbina F. Puhl A.C. In silico ADME/tox comes of age: Twenty years later. Xenobiotica 2024 54 7 352 358 10.1080/00498254.2023.2245049 37539466
    [Google Scholar]
  37. Kar S. Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin. Drug Discov. 2020 15 12 1473 1487 10.1080/17460441.2020.1798926 32735147
    [Google Scholar]
  38. Ferreira L.L.G. Andricopulo A.D. ADMET modeling approaches in drug discovery. Drug Discov. Today 2019 24 5 1157 1165 10.1016/j.drudis.2019.03.015 30890362
    [Google Scholar]
  39. Cáceres E.L. Tudor M. Cheng A.C. Deep learning approaches in predicting ADMET properties. Future Med. Chem. 2020 12 22 1995 1999 10.4155/fmc‑2020‑0259 33124448
    [Google Scholar]
  40. Beckers M. Sturm N. Sirockin F. Fechner N. Stiefl N. Prediction of small-molecule developability using large-scale in silico ADMET models. J. Med. Chem. 2023 66 20 14047 14060 10.1021/acs.jmedchem.3c01083 37815201
    [Google Scholar]
  41. Aksamit N. Tchagang A. Li Y. Ombuki-Berman B. Hybrid fragment-SMILES tokenization for ADMET prediction in drug discovery. BMC Bioinformatics 2024 25 1 255 10.1186/s12859‑024‑05861‑z 39090573
    [Google Scholar]
  42. Freshney R.I. Culture of Animal Cells: A manual of basic techniques. 2nd Ed. New York Wiley-Liss 1987 1 4
    [Google Scholar]
  43. Capes-Davis A. Freshney R.I. Freshney’s Culture of animal cells: A manual of basic technique and specialized applications. 8th Ed. New York Wiley-Blackwel 2021 1 6
    [Google Scholar]
  44. Sá M.M. Ferreira M. Bortoluzzi A.J. Fernandes L. Cunha S. Exploring the reaction of multifunctional allylic bromides with N,S-dinucleophiles: Isothiouronium salts and analogs as useful motifs to assemble the 1,3-thiazine core. ARKIVOC 2010 2010 11 303 321 10.3998/ark.5550190.0011.b24
    [Google Scholar]
  45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Meth. 1983 65 1-2 55 63 10.1016/0022‑1759(83)90303‑4 6606682
    [Google Scholar]
  46. Das S. Roayapalley P.K. Sakagami H. Umemura N. Gorecki D.K.J. Hossain M. Kawase M. Das U. Dimmock J.R. Dimeric 3,5-Bis(benzylidene)-4-piperidones: Tumor-selective cytotoxicity and structure-activity relationships. Medicines (Basel) 2024 11 1 3 10.3390/medicines11010003 38248717
    [Google Scholar]
  47. Daina A. Michielin O. Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017 7 1 42717 10.1038/srep42717 28256516
    [Google Scholar]
  48. Wahl A.F. Donaldson K.L. Faircnild C. Lee F.Y.F. Foster S.A. Demers G.W. Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 1996 2 1 72 79 10.1038/nm0196‑72 8564846
    [Google Scholar]
  49. Assunção L.S. Kretzer I.F. Sierra Restrepo J.A. de Mello Junior L.J. Silva A.H. de Medeiros Oliveira E. Ferreira M. Sá M.M. Creczynski-Pasa T.B. Antitumor activity of methyl (Z)-2-(isothioureidomethyl)-2-pentenoate hydrobromide against leukemia cell lines via mitotic arrest and apoptotic pathways. Biochim. Biophys. Acta, Gen. Subj. 2019 1863 9 1332 1342 10.1016/j.bbagen.2019.05.018 31170497
    [Google Scholar]
  50. Lica J.J. Wieczór M. Grabe G.J. Heldt M. Jancz M. Misiak M. Gucwa K. Brankiewicz W. Maciejewska N. Stupak A. Bagiński M. Rolka K. Hellmann A. Składanowski A. Effective Drug concentration and selectivity depends on fraction of primitive cells. Int. J. Mol. Sci. 2021 22 9 4931 10.3390/ijms22094931 34066491
    [Google Scholar]
  51. van den Bosch Q.C.C. Kiliç E. Brosens E. Uveal Melanoma Zebrafish Xenograft Models illustrate the mutation status-dependent effect of compound synergism or antagonism. Invest. Ophthalmol. Vis. Sci. 2024 65 10 26 10.1167/iovs.65.10.26 39163035
    [Google Scholar]
  52. Sherr C.J. Principles of tumor suppression. Cell 2004 116 2 235 246 10.1016/S0092‑8674(03)01075‑4 14744434
    [Google Scholar]
  53. Clarke P.R. Allan L.A. Cell-cycle control in the face of damage – a matter of life or death. Trends Cell Biol. 2009 19 3 89 98 10.1016/j.tcb.2008.12.003 19168356
    [Google Scholar]
  54. Alshwyeh H.A. Al-Sheikh W.M.S. Rasedee A. Alnasser S.M. Al-Qubaisi M.S. Ibrahim W.N. Mangifera indica L. kernel ethanol extract inhibits cell viability and proliferation with induction of cell cycle arrest and apoptosis in lung cancer cells. Mol. Cell. Oncol. 2024 11 1 2299046 10.1080/23723556.2023.2299046 38196561
    [Google Scholar]
  55. Lee J.M. Lee W.H. Cho S.H. Park J.W. Kwon H.N. Kim J.H. Lee S.H. Yoon J.H. Park S. Kim S.C. DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment. Investig. Clin. Urol. 2025 66 1 56 66 10.4111/icu.20240263 39791585
    [Google Scholar]
  56. Koronkiewicz M. Kazimierczuk Z. Szarpak K. Chilmonczyk Z. Proapoptotic effects of new pentabromobenzylisothiouronium salts in a human prostate adenocarcinoma cell line. Acta Pol. Pharm. 2012 69 6 1325 1333 23285698
    [Google Scholar]
  57. Hoose S.A. Duran C. Malik I. Eslamfam S. Shasserre S.C. Downing S.S. Hoover E.M. Dowd K.E. Smith R. III Polymenis M. Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine. PLoS One 2012 7 5 e36503 10.1371/journal.pone.0036503 22567160
    [Google Scholar]
  58. Arjona M.I. Duch M. Hernández-Pinto A. Vázquez P. Agusil J.P. Gómez-Martínez R. Redondo-Horcajo M. Amirthalingam E. Pérez-García L. Suárez T. Plaza J.A. Intracellular mechanical drugs induce cell‐cycle altering and cell death. Adv. Mater. 2022 34 17 2109581 10.1002/adma.202109581 35174908
    [Google Scholar]
  59. Hira A. Zhang J. Kadakia M.P. TIP60 enhances cisplatin resistance via regulating ΔNp63α acetylation in SCC. Cell Death Dis. 2024 15 12 877 10.1038/s41419‑024‑07265‑6 39627186
    [Google Scholar]
  60. Środa-Pomianek K. Barycka A. Gleńsk M. Rajbhandari M. Skonieczna M. Palko-Łabuz A. Wesołowska O. Pretreatment of melanoma cells with aqueous ethanol extract from Madhuca longifolia Bark strongly potentiates the activity of a low dose of dacarbazine. Int. J. Mol. Sci. 2024 25 13 7220 10.3390/ijms25137220 39000329
    [Google Scholar]
  61. Andree H.A. Reutelingsperger C.P. Hauptmann R. Hemker H.C. Hermens W.T. Willems G.M. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J. Biol. Chem. 1990 265 9 4923 4928 10.1016/S0021‑9258(19)34062‑1 2138622
    [Google Scholar]
  62. Bevers E.M. Comfurius P. Dekkers D.W.C. Zwaal R.F.A. Lipid translocation across the plasma membrane of mammalian cells. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1999 1439 3 317 330 10.1016/S1388‑1981(99)00110‑9 10446420
    [Google Scholar]
  63. Mizushima N. Autophagy: Process and function. Genes Dev. 2007 21 22 2861 2873 10.1101/gad.1599207 18006683
    [Google Scholar]
  64. Levine B. Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008 132 1 27 42 10.1016/j.cell.2007.12.018 18191218
    [Google Scholar]
  65. Noda N.N. Inagaki F. Mechanisms of autophagy. Annu. Rev. Biophys. 2015 44 1 101 122 10.1146/annurev‑biophys‑060414‑034248 25747593
    [Google Scholar]
  66. Luo Y. Liu R. Zhang H. Wang H. Yin H. Tian G. Wang B. Yan Y. Ding Z. Dai J. Niu L. Yuan G. Pan Y. Amantadine against glioma via ROS-mediated apoptosis and autophagy arrest. Cell Death Dis. 2024 15 11 834 10.1038/s41419‑024‑07228‑x 39548081
    [Google Scholar]
  67. Lipinski C.A. Lombardo F. Dominy B.W. Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article. Adv. Drug Deliv. Rev. 2001 46 1-3 3 26 10.1016/S0169‑409X(00)00129‑0 11259830
    [Google Scholar]
  68. Veber D.F. Johnson S.R. Cheng H.Y. Smith B.R. Ward K.W. Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002 45 12 2615 2623 10.1021/jm020017n 12036371
    [Google Scholar]
  69. Dong J. Yuan L. Hu C. Cheng X. Qin J.J. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review. Pharmacol. Ther. 2023 249 108488 10.1016/j.pharmthera.2023.108488 37442207
    [Google Scholar]
  70. Hakkola J. Hukkanen J. Turpeinen M. Pelkonen O. Inhibition and induction of CYP enzymes in humans: An update. Arch. Toxicol. 2020 94 11 3671 3722 10.1007/s00204‑020‑02936‑7 33111191
    [Google Scholar]
  71. Lee J. Beers J.L. Geffert R.M. Jackson K.D. A review of CYP-mediated drug interactions: Mechanisms and in vitro drug-drug interaction assessment. Biomolecules 2024 14 1 99 10.3390/biom14010099 38254699
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206358941250413154017
Loading
Methyl (Z)-2-(Isothioureidomethyl)-2-pentenoate Hydrobromide Induces Cell Cycle Arrest and Disrupts Mitosis in a Melanoma Cell Line
Bentham Science Publishers ; https://doi.org/10.2174/0118715206358941250413154017
/content/journals/acamc/10.2174/0118715206358941250413154017
/content/journals/acamc/10.2174/0118715206358941250413154017
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: Antitumor activity ; cancer ; B16F10 ; apoptosis ; isothiouronium salts ; melanoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test